Due to the ongoing Covid-19 situation, global travel restrictions and new limitations on in-person events we are unable to run the 30th MedTech Investing Europe Conference in-person in Lausanne. We will instead be building on this year’s online series of events and be hosting the event digitally, on the revised dates of 21-22 October 2020. Attendees will be able to participate online and benefit from everything the MTI events normally offer – industry leading content, speakers from some of the world’s foremost investors and importantly dedicated networking for both investors and presenting companies. Attendees are required to pre-register and will receive full details, access links and schedule in advance of the event.
Benefits of attending
Bringing Together Innovators, Leading Investors and Major Healthcare Corporations
Welcome to the 30th MedTech Investing Europe Conference, the longest-established and leading healthcare investment and partnering conference in Europe. We are delighted to once again bring together the very best game-changing technologies and leading entrepreneurs with a wide range of healthcare investors including VC’s, angel investors, leading MedTech corporations, private wealth holders, family offices and many more.
Since 2003 we have been at the centre of the rapidly evolving healthcare technology venture ecosystem and specialised in bringing together over 1000 venture-stage companies with investors ranging from VC’s to major healthcare corporations, from family offices to angel investors and many more.
This unrivalled platform will:
The MTI events deliver the best ratio of investors to presenting companies, giving all attendees the maximum opportunity to meet, network and learn from the best in the business ensuring you meet the right investors and the right investment opportunities.
Do not miss this unique opportunity to meet with some of the most proactive entrepreneurs and investors in healthcare, learn how to fine-tune your strategy and ultimately maximise the potential for return from the sector.
The MTI conference programmes address the biggest topics in the industry today, from investment topics such as “Where is the money coming from?” and “What do family offices look for and how do they invest?” to wider challenges such as “How does healthcare economics playout in the real world?” and “How do you plan and execute a successful exit”.
The conference programmes are developed in conjunction with the MTI Investor Advisory Board – a collection of the biggest investors in the sector with assets under management of over €40bn.
Our speaking faculties represent the truly global nature of the healthcare and life science industry with panellists drawn from leading organisations from Europe, North America, the Middle East and Asia.
The core of our speaker faculty is made-up of some of the industry’s most active and ambitious investors joining on-stage discussion to give the latest insight into their investment strategy, the evolution of the sector, the most promising future opportunities and ultimately the opportunities they are looking for and to make investments in.
Leading the conference programme we are honoured to welcome back as conference chairman Dr Benoît Dubuis the Executive Director of Campus Biotech and the President of the world-renowned Inartis Foundation.
Benoît has over 30 years of international experience in Life Sciences, both in industry and in the academic world. After his engineering training, his doctorate from ETH Zurich (ETH Medal 1995) and an academic activity in Cambridge and Cranfield in England, he held various management positions in pharmaceutical companies (Chemap, Ciba-Geigy / Novartis, Lonza), before joining the École Polytechnique Fédérale de Lausanne (EPFL) where he founded the Faculty of Life Sciences.
Confirmed speakers will be updated at regular intervals as the events draws closer. If you are interested in speaking at the event please contact the event manager:
+44(0)203 763 2800
Over the last 29 events we have showcased over 1000 venture-stage healthcare and life science companies to our unrivalled audience of investors. Representing all areas of healthcare and life sciences our presenting companies originate from over 37 countries and are at a range of different stages from pre-clinical to commercialisation.
For more information on how you can participate please email MouniraRuma@campdenwealth.com.
A selection of the previously confirmed presenting companies at MTI events include:
Why attend as a delegate?
Be the first to uncover the latest investment opportunities from our unrivalled range of Presenting Companies
Meet over 40 investment opportunities over duration of 2 days
Network with the leading investors and MedTech corporations
Learn how to adapt your investment strategy for today’s climate
Take away the tools to help your portfolio companies develop and grow to their full potential
Who are the delegates?
Every year MTI brings over 150 delegates together who are working at the cutting edge of healthcare and life science investment and partnering. Our investors represent some of the most pro-active and ambitious individuals from family offices, private wealth holders, VC’s, corporate VC’s, institutional investors, angels and managed funds to name but a few.
In order to ensure the best possible mix of investors and early-stage companies admission to all MTI events is strictly controlled and open to all qualifying companies and individuals. The organisers reserve the right to restrict admittance and delegate places.
To see examples of the range of investors MTI attracts here are just some of our previous members of the Investor Advisory Board:
Partner, Siemens Venture Capital, USA
General Partner, BioMed Partners, Switzerland
General Partner, VI Partners, Switzerland
Senior Managing Director, OrbiMed Healthcare Fund Management, Israel
Partner, Gilde Healthcare Partners, Netherlands
Managing Partner, Peppermint Venture Partners GmbH, Germany
Partner, Omega Fund Management, UK
Co-Head Venture Capital, Life Sciences Partner, Omnes Capital, France
Founding Partner, HealthCap Venture Capital, Sweden
President, Shafner Law Office, USA
How to register
Special packages and early booking price are now available, see the Registration Page for more information or contact:
+44 (0)203 763 2816
Sponsors of the MTI events represent leading companies and organisations providing services to early to mid-stage life science companies, investors and major healthcare corporations. Sponsors receive unrivalled exposure and access to some of the smartest venture-stage companies, cutting-edge investors and active family offices:
Canton of Vaud
State of Vaud - Office for Economic Affairs and Innovation (SPEI)
Canton of Vaud is one of the main centers of research and innovation in Switzerland, with the largest academic and technology campus in the country and several research institutes as well as industries of international reputation, particularly in life sciences, micro-nanotechnologies, ICT and cleantech.
In a few words :
A quarter of the 100 top Swiss startups are based in Vaud including 4 of the 10 top best ones in 2018 as well as about 2,000 high-tech companies
Vaud ranked 1st in fundraising for 4 consecutive years (2014-2017) in comparison to other Swiss cantonsas Vaud-based startups have raised up to CHF 1.2 bio over the past 5 years and CHF 267.5 mio in 2018
24 scaleups are based in Vaud and created 361 new jobs in 2018
There are 7 incubators and innovation parks suitable to develop your ideas and business, pooling local infrastructure and technical skills
About CHF +32 mio financial incentives have been distributed from the State of Vaud to startups/SMEs since 2012 to support their economic development.
Through its support to the MedTech Investing Europe Conference 2020, SPEI aims to showcase our region to all the international guests for what it really is: a direct connection with world-class academic and research institutes, a dense network of internationally oriented SMEs and innovative startups, and a vibrant location offering favorable conditions to expand your business.
The Office for Economic Affairs and Innovation (SPEI) supports companies that are exclusively based in Vaud, especially those involved in the sectors of advanced technology and industry. SPEI advises entrepreneurs and puts them in contact with organizations that are appropriate to their specific needs. SPEI can also provide direct financial support.
For more information, please contact:
State of Vaud – Department of Economy, Innovation and Sport (DEIS)
Office for Economic Affairs and Innovation (SPEI)
Rue Caroline 11
CH – 1014 Lausanne
+41 21 316 58 20
BioAlps - The Lake Geneva Biotech & Medtech Cluster
BioAlps is the life science cluster of Western Switzerland. The association is an active and growing network of research institutions, academic institutions, start-up companies and large, blue chip multinationals.
The biotech and medtech sectors in BioAlps are experiencing double digit annual growth and have attracted more than CHF 500'000'000 venture capitalist investments in 2017.
The BioAlps region includes:
1118 life sciences companies
500+ research laboratories
35,000+ people employed in companies
33 research institutions, universities and university hospitals
Many science parks and incubators for start-up companies
The BioAlps region offers many assets for attracting companies and start-ups:
Strong, dynamic and economy-friendly academic research: efficient technology transfer practices
Most favourable tax rulings and conditions in Europe, particularly for new companies and international corporate structures
Incubators offering lab space, coaching and financial support
Flexibility of labour market and labour relations
Strong VC presence and public financial tools for boosting young companies’ development
Easy to attract the best scientists and managers thanks to an exceptional quality of life
Exceptional competencies in the domains of molecular and genetic biology, bioinformatics, proteomics and genomics, oncology, neurosciences, as well as in pharmaceuticals, instrumentation, diagnostics and medical devices
The BioAlps Association:
Promotes and strengthens synergies among its members in the academic and private sectors
Fully supports the transfer of technologies and competencies from academic to industrial settings
Stimulates the development of new businesses
Develops the exchange of information and resources between scientists, the financial community and government representatives
Establishes relationships with similar initiatives in life sciences at the local and national levels
Provides a communication network throughout Switzerland and internationally in which to disseminate information on its initiatives
Offers a close and friendly biotech and medtech community
For more information, please contact:
Avenue de Sécheron 15
École Polytechnique Fédérale de Lausanne, EPFL, is located on the shores of Lake Geneva in Switzerland. It has three missions: education, research and technology transfer at the highest international level. With more than 250 laboratories and research groups on campus, it is one of Europe’s most innovative and productive technology institutes.
The campus offers services and facilities to transform scientific excellence into economic competitiveness, jobs and quality of life. A start-up incubator, coaching services, study programmes in entrepreneurship and innovation programmes all serve to stimulate the links between the lab and business. The Science Park on campus is home to more than 100 enterprises and numerous investors. EPFL’s unique structure facilitates transdisciplinary research and encourages partnerships with other institutions. It emphasizes both fundamental research and engineering applications. Within the EPFL School of Engineering (STI) a wide range of laboratories are active in the field of biomedical technologies, notably in optics and imaging, medical engineering, instrumentation and biomedical signal processing.
The focus is placed on the integration of natural and artificial systems at several levels: development of new models inspired by living organisms, conception of components, tools and systems to facilitate the understanding of the functions of living systems and finally, conception and development of increasingly sophisticated medical aids. A particular emphasis is placed on biomechanics, including mechanical properties and behavior of living tissue and biomaterials, bone mechanics, biomechanics and orthopaedics, prostheses and implants and movement analysis and measurement.
It is clear that biomedical research will increasingly rely on quantitative approaches and high-end technologies. The future of life sciences lies at the crossroads of biology, hard sciences and engineering.
The EPFL School of Life Sciences (SV) was created on this premise, reflecting the thirst for biologically relevant questions amongst EPFL experts in chemistry, physics, mathematics, computer science and engineering. It comprises four institutes active in neuroscience, bioengineering, infectious diseases and cancer. Integrated approaches are pushed spanning a wide range of disciplines from functional genomics to high-tech bioengineering. In addition to the main Lausanne campus, the SV is present at the Campus Biotech in Geneva with initiatives in neuroprosthetics, the Human Brain Project and a center for Bio and Neuroengineering.
To enquire about sponsorship opportunities at upcoming MTI events, please contact Peter Newton on firstname.lastname@example.org
Campden Wealth, 30 Cannon Street, Lower Ground Floor, London EC4M 6XH, United Kingdom